Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Validation of the new pathology staging system for progressive supranuclear palsy

Mayen Briggs, Kieren SJ Allinson, View ORCID ProfileMaura Malpetti, Maria Grazia Spillantini, James Benedict Rowe, View ORCID ProfileSanne Simone Kaalund
doi: https://doi.org/10.1101/2021.01.18.21250017
Mayen Briggs
1Cambridge University Hospitals NHS Foundation Trust and the Cambridge Brain Bank, CB2 2QQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kieren SJ Allinson
1Cambridge University Hospitals NHS Foundation Trust and the Cambridge Brain Bank, CB2 2QQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maura Malpetti
2Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ
3Cambridge Centre for Parkinson-plus, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maura Malpetti
Maria Grazia Spillantini
4Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Clifford Allbutt Building, Cambridge, CB2 0AH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Benedict Rowe
2Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ
3Cambridge Centre for Parkinson-plus, University of Cambridge
5Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, UK, CB2 7EF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanne Simone Kaalund
2Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ
3Cambridge Centre for Parkinson-plus, University of Cambridge
4Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Clifford Allbutt Building, Cambridge, CB2 0AH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanne Simone Kaalund
  • For correspondence: ssk42@medschl.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder associated with neuroglial accumulation of 4-repeat tau protein. Kovacs et al. have recently proposed a new semi-quantitative staging system to categorise the severity of PSP pathology, using the distribution of tau aggregates as it progresses from subcortical to cerebellar and cortical regions. Here, we test the new PSP pathology staging system in an independent series of PSP, and test the potential association between pathology stage and clinical severity at death. We include tissue from 35 people with a clinical diagnosis of PSP (including N=25 with Richardson’s syndrome and N=10 with other phenotypes). Donors had attended longitudinal clinical studies at the Cambridge Centre Parkinson-plus including assessment of clinical severity by the PSP rating scale (PSPRS) and cognitive performance by the revised Addenbrooke’s Cognitive Examination (ACE-R). We rated tau pathology from none-to-severe in six regions. We focused on (I) astrocytic tau inclusions in striatum, frontal and occipital regions, and (II) neuronal and oligodendroglia tau inclusions in globus pallidus, subthalamic nucleus, and cerebellum. Thirty-two cases (91%) readily conformed to the new staging system, ranging from stage 2 to 6. Staging system applied to brains from people with different clinical phenotypes of PSP. Neuropathology stages correlated with clinical severity at death using both PSPRS and ACE-R, weighted for the interval between last assessment and donation. Our study supports the proposed sequential distribution of tau aggregates in PSP pathology, and the hypothesised relationship between clinical and neuropathological severity. For future studies, in order to standardise rating between centres, we propose a set of operational criteria for region-specific thresholds or tau burden, and a visual guide.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by the Cambridge Brain Bank, Wellcome Trust (103838/Z/14/Z); Medical Research Council (Ref: 146281), and the Cambridge Centre for Parkinson plus (RG95450). The Cambridge Brain Bank is supported by the NIHR Cambridge Biomedical Research Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study ethics was approved by the Health Research Authority, NHS, England (IRAS- 202 802, Neurodegeneration Research in Dementia). The PiPPIN (Pick's Disease and Progressive Supranuclear Palsy: Prevalence and Incidence) Study was approved by Cambridge's research ethics committee. The study was conducted in accordance with the 1964 Helsinki declaration.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Validation of the new pathology staging system for progressive supranuclear palsy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Validation of the new pathology staging system for progressive supranuclear palsy
Mayen Briggs, Kieren SJ Allinson, Maura Malpetti, Maria Grazia Spillantini, James Benedict Rowe, Sanne Simone Kaalund
medRxiv 2021.01.18.21250017; doi: https://doi.org/10.1101/2021.01.18.21250017
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Validation of the new pathology staging system for progressive supranuclear palsy
Mayen Briggs, Kieren SJ Allinson, Maura Malpetti, Maria Grazia Spillantini, James Benedict Rowe, Sanne Simone Kaalund
medRxiv 2021.01.18.21250017; doi: https://doi.org/10.1101/2021.01.18.21250017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pathology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (189)
  • Epidemiology (5208)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (748)
  • Geriatric Medicine (76)
  • Health Economics (212)
  • Health Informatics (691)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5806)
  • Intensive Care and Critical Care Medicine (355)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (474)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1989)
  • Radiology and Imaging (342)
  • Rehabilitation Medicine and Physical Therapy (155)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)